Moleculin Biotech is trading 5.9% lower at $0.54; the provided information does not establish a catalyst for the decline.

  • Shares closed down 5.42% at $0.57 on September 28, extending a volatile stretch; broader market indexes were only slightly lower.
  • On September 29, Moleculin announced that enrollment in Part A of its Phase 2/3 MIRACLE trial had closed with 89 subjects enrolled. A comprehensive data readout is expected in Q1 2027.
  • A peer-reviewed cardiac-safety analysis was announced September 28, but it is not a clear explanation for the decline.